Sarju Ganatra

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7322512/publications.pdf

Version: 2024-02-01

61	3,809	304743	189892
papers	citations	22 h-index	50 g-index

67	67	67	3487
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. Journal of the American College of Cardiology, 2018, 71, 1755-1764.	2.8	997
2	Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Annals of Oncology, 2020, 31, 171-190.	1.2	582
3	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. European Heart Journal, 2022, 43, 280-299.	2.2	213
4	Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. European Heart Journal, 2020, 41, 1733-1743.	2.2	212
5	Immune Checkpoint Inhibitor-Associated Myocarditis. Oncologist, 2018, 23, 879-886.	3.7	207
6	Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis. Journal of the American College of Cardiology, 2020, 75, 467-478.	2.8	179
7	Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitorâ€“Associated Myocarditis. Circulation, 2020, 141, 2031-2034.	1.6	142
8	Ibrutinib-Associated Atrial Fibrillation. JACC: Clinical Electrophysiology, 2018, 4, 1491-1500.	3.2	134
9	Myocardial T1 and T2 Mapping by Magnetic Resonance in PatientsÂWithÂImmune Checkpoint Inhibitorâ€“Associated Myocarditis. Journal of the American College of Cardiology, 2021, 77, 1503-1516.	2.8	97
10	The Novel Coronavirus Disease (COVID-19) Threat for Patients With Cardiovascular Disease and Cancer. JACC: CardioOncology, 2020, 2, 350-355.	4.0	92
11	Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors. Cardio-Oncology, 2019, 5, 18.	1.7	87
12	Cardiotoxicity of Immune Checkpoint Inhibitors. Current Oncology Reports, 2021, 23, 79.	4.0	85
13	Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart. Journal of the American College of Cardiology, 2019, 74, 3153-3163.	2.8	78
14	Chimeric Antigen Receptor T-Cell Therapyâ€“Associated Cardiomyopathy in Patients With Refractory or Relapsed Non-Hodgkin Lymphoma. Circulation, 2020, 142, 1687-1690.	1.6	70
15	Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors. , 2019, 7, 53.		59
16	Management of Patients With Giant Cell Myocarditis. Journal of the American College of Cardiology, 2021, 77, 1122-1134.	2.8	59
17	Preparing the Cardiovascular Workforce to Care for Oncology Patients. Journal of the American College of Cardiology, 2019, 73, 2226-2235.	2.8	56
18	Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series. Cardio-Oncology, 2019, 5, 1.	1.7	54

#	Article	IF	Citations
19	Cardiotoxicity of Immune Therapy. Cardiology Clinics, 2019, 37, 385-397.	2.2	54
20	Management of Cardiovascular Disease During Coronavirus Disease (COVID-19) Pandemic. Trends in Cardiovascular Medicine, 2020, 30, 315-325.	4.9	44
21	Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. , 2021, 9, e002007.		36
22	Cardiotoxicity of Contemporary Anticancer Immunotherapy. Current Treatment Options in Cardiovascular Medicine, 2020, 22, 62.	0.9	34
23	Cardioâ€oncology care in the era of the coronavirus disease 2019 (COVIDâ€19) pandemic: An International Cardioâ€Oncology Society (ICOS) statement. Ca-A Cancer Journal for Clinicians, 2020, 70, 480-504.	329.8	29
24	Niacinamide May Be Associated with Improved Outcomes in COVID-19-Related Acute Kidney Injury: An Observational Study. Kidney360, 2021, 2, 33-41.	2.1	23
25	Re-Evaluating the Safety of Drug-ElutingÂStents in Cancer Patients. JACC: Cardiovascular Interventions, 2017, 10, 2334-2337.	2.9	22
26	Outcomes of COVID-19 in Patients With a History of Cancer and Comorbid Cardiovascular Disease. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, , 1-10.	4.9	22
27	Cardio-Oncology for GenNext. Journal of the American College of Cardiology, 2018, 71, 2977-2981.	2.8	20
28	Risk and predictors of dyssynchrony cardiomyopathy in left bundle branch block with preserved left ventricular ejection fraction. Clinical Cardiology, 2020, 43, 1494-1500.	1.8	8
29	Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience. Open Heart, 2021, 8, e001849.	2.3	8
30	Without Further Delay: Lyme Carditis. American Journal of Medicine, 2018, 131, 384-386.	1.5	7
31	Angioedema with sacubitril/valsartan: Trial-level meta-analysis of over 14,000 patients and real-world evidence to date. International Journal of Cardiology, 2021, 323, 188-191.	1.7	7
32	Angiotensin II Administration in Patients With COVID-19 Shock. Critical Pathways in Cardiology, 2021, 20, 100-102.	0.5	7
33	Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital. JCO Clinical Cancer Informatics, 2022, , .	2.1	7
34	Intracranial hemorrhage in a patient with subâ€massive pulmonary embolism treated with EkoSonic endovascular system directed thrombolysis. Catheterization and Cardiovascular Interventions, 2017, 90, 476-479.	1.7	6
35	How to Diagnose and Manage Radiation Cardiotoxicity. JACC: CardioOncology, 2020, 2, 655-660.	4.0	6
36	A Dual-Snare Percutaneous Retrieval ofÂVenous Stent Embolization toÂtheÂRightÂHeart. JACC: Cardiovascular Interventions, 2017, 10, e111-e113.	2.9	6

#	Article	IF	Citations
37	Mycobacterium Chimaera Mimicking Sarcoidosis. Methodist DeBakey Cardiovascular Journal, 2021, 14, 301.	1.0	6
38	Implementation of Cardio-Oncology Training for Cardiology Fellows. JACC: CardioOncology, 2020, 2, 795-799.	4.0	6
39	Disparities in Cardio-oncology: Effects On Outcomes and Opportunities for Improvement. Current Cardiology Reports, 2022, 24, 1117-1127.	2.9	6
40	CHALLENGES IN IBRUTINIB ASSOCIATED ATRIAL FIBRILLATION. Journal of the American College of Cardiology, 2017, 69, 2308.	2.8	5
41	A Differing Opinion on Primary Percutaneous Coronary Intervention in Patients Who Have Had Cancer: Stent Choice in Onco-cardiology Revisited. Mayo Clinic Proceedings, 2017, 92, 1315-1316.	3.0	5
42	The Impact of Atrial Fibrillation on hospitalization Outcomes for Patients With Chronic Lymphocytic Leukemia Using the National Inpatient Sample Database. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 98-104.	0.4	5
43	Caseâ€control study of heart rate abnormalities across the breast cancer survivorship continuum. Cancer Medicine, 2019, 8, 447-454.	2.8	4
44	Pharmacomechanical Therapy for Deep-Vein Thrombosis. New England Journal of Medicine, 2018, 378, 1752-1753.	27.0	2
45	Cardiotoxicity Monitoring in Patients With Cancer: Focus on Safety and Clinical Relevance. JCO Oncology Practice, 2021, 17, 237-239.	2.9	2
46	T-cell Immunotherapy and Cardiovascular Disease. Heart Failure Clinics, 2022, 18, 443-454.	2.1	2
47	Editorial commentary: Cardiovascular imaging in COVID-19: Focus on safety, value, and clinical relevance. Trends in Cardiovascular Medicine, 2021, 31, 17-19.	4.9	1
48	Overuse of Cardiac Testing. American Family Physician, 2018, 98, 561-563.	0.1	1
49	Oral anticoagulation therapies among Medicare beneficiaries: Utilization and costs. Vascular Medicine, 2022, 27, 490-492.	1.5	1
50	EXPANDING THE ROLE OF DEXRAZOXANE FOR CARDIOPROTECTION: USE IN A PATIENT WITH PRE-EXISTING SYSTOLIC DYSFUNCTION AND NO PRIOR ANTHRACYCLINE EXPOSURE. Journal of the American College of Cardiology, 2017, 69, 2389.	2.8	0
51	Incidence of Primary, Dilated Rather Than Tachycardia-Induced Cardiomyopathy among Patients Presenting with New Onset Atrial Arrhythmia and Heart Failure with Reduced Ejection Fraction. Journal of Cardiac Failure, 2019, 25, S82.	1.7	0
52	BLEOMYCIN PERICARDIAL SCLEROSIS: A SAFE AND EFFECTIVE THERAPY FOR MALIGNANT PERICARDIAL EFFUSION. Journal of the American College of Cardiology, 2020, 75, 3319.	2.8	0
53	ANGIOEDEMA WITH SACUBITRIL/VALSARTAN: TRIAL-LEVEL META-ANALYSIS OF OVER 15,000 PATIENTS & REAL-WORLD EVIDENCE TO DATE. Journal of the American College of Cardiology, 2020, 75, 791.	2.8	0
54	Lack of Association Between Left Ventricular Dyssynchrony and The Development of Cardiomyopathy in Patients with Left Bundle Branch Block and Initially Preserved Left Ventricular Ejection Fraction. Journal of Cardiac Failure, 2020, 26, S29.	1.7	0

#	Article	IF	Citations
55	Acute Heart Failure and Atrial Fibrillation with Rapid Ventricular Response - Role of Gender and Alcohol in Suspected Tachycardia-induced Cardiomyopathy. Journal of Cardiac Failure, 2020, 26, S77.	1.7	0
56	B-PO04-140 TRENDS AND OUTCOMES OF ARRHYTHMIA IN CHRONIC LYMPHOCYTIC LEUKEMIA HOSPITALIZATIONS. Heart Rhythm, 2021, 18, S336-S337.	0.7	0
57	Strategies to balance stroke and bleeding risk in patients with atrial fibrillation and cancer. Heart Rhythm, 2021, 18, 1533-1538.	0.7	0
58	A rare form of imported infectious heart block. Grand Rounds, 2013, 13, 27-29.	0.2	0
59	Hypothyroidism and the Heart: Much More Than Meets the Eye. Methodist DeBakey Cardiovascular Journal, 2021, 13, 261.	1.0	0
60	Propafenone Induced 1:1 Atrial Flutter Conduction. Cardiovascular Pharmacology: Open Access, 2018, 07, .	0.1	0
61	Abstract 174: Healthcare Provider Compliance with the 2013 ACC/AHA Blood Cholesterol Guidelines for Statin Therapy for Diabetic Patients of Ages 40 to 75. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, .	2.2	0